 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Immediate versus Delayed Treatment for HIV Infection
15 April 2003 | Volume 138 Issue 8 | Page I-28
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+Cell Strata." It is in the 15 April 2003 issue of Annals of Internal Medicine (volume 138, pages 620-626). The authors are F.J. Palella Jr., M. Deloria-Knoll, J.S. Chmiel, A.C. Moorman, K.C. Wood, A.E. Greenberg, S.D. Holmberg, and the HIV Outpatient Study (HOPS) Investigators.
What is the problem and what is known about it so far?
HIV is the cause of AIDS. AIDS is a potentially deadly illness that interferes with the body's ability to fight infection and certain types of cancer. Treatments containing several drugs (called antiretroviral therapy) have greatly improved outcomes for HIV-infected patients. A powerful category of drugs called protease inhibitors can be particularly effective. Patients often have difficulty adhering to these treatments, however, because they need to take many pills several times a day and side effects are common. The best time to start antiretroviral therapy for HIV infection is controversial. Starting too early exposes patients to side effects, and the benefits of such early therapy are unclear. Starting too late deprives patients of the benefits. Doctors use blood tests called CD4 cell counts and HIV viral loads to determine when they should start treatment for HIV. CD4 cell counts decrease as the disease advances, so higher counts are desirable. Viral load increases as the disease advances, so starting therapy at lower viral loads is more desirable.
Why did the researchers do this particular study?
To find out whether patients with HIV infection do better if they start therapy earlier in the course of HIV infection rather than waiting until their CD4 count decreases.
Who was studied?
1464 patients with HIV infection who were participating in larger study called the HIV Outpatient Study (HOPS). Patients could be included in this study if they had no previous HIV treatment and had undergone multiple CD4 and viral load tests.
How was the study done?
The researchers divided the patients into three groups according to the CD4 count when they entered the study: 0.201 to 0.350 x 109 cells/L, 0.351 to 0.500 x 109 cells/L, or 0.501 to 0.750 x 109 cells/L. They then compared the death rates in people who started treatment immediately with the death rates in people who started treatment after their CD4 count decreased.
What did the researchers find?
For people with a CD4 count of 0.201 to 0.350 x 109 cells/L, those who started treatment did better (that is, death rates were lowered) than those who delayed treatment. For people with higher CD4 counts (0.351 to 0.500 x 109 cells/L or 0.501 to 0.750 x 109 cells/L), death rates were again lower for those who started treatment than for those who delayed treatment; however, we cannot be sure that this finding is real because it was based on too few cases. For those with the highest CD4 counts (0.501 to 0.750 x 109 cells/L), death rates were similar regardless of whether people started or delayed treatment. People who started rather than delayed therapy when their initial CD4 count was 0.201 to 0.350 x 109 cells/L or 0.351 to 0.500 x 109 cells/L were more likely to have an undetectable viral load, which suggests that the drugs effectively fight HIV.
What were the limitations of the study?
Because of its design, this study could not identify the best time to start HIV treatment with certainty.
What are the implications of the study?
This study suggests that it may be reasonable to start HIV treatment immediately in patients with CD4 counts of 0.350 x 109 cells/L or less rather than waiting for the CD4 count to drop further. However, for patients with CD4 counts greater than 0.350 x 109 cells/L, it is less clear whether therapy should begin immediately or after CD4 counts decrease further.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. S. Braithwaite, M. S. Roberts, C. C. H. Chang, M. B. Goetz, C. L. Gibert, M. C. Rodriguez-Barradas, S. Shechter, A. Schaefer, K. Nucifora, R. Koppenhaver, et al. Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model Ann Intern Med, February 5, 2008; 148(3): 178 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shechter, M. D. Bailey, A. J. Schaefer, and M. S. Roberts The Optimal Time to Initiate HIV Therapy Under Ordered Health States Operations Research, January 1, 2008; 56(1): 20 - 33. [Abstract] [PDF]
|
|
|
|
 |
|
 Missed Opportunities for Earlier Diagnosis of HIV Infection--South Carolina, 1997-2005 JAMA, January 10, 2007; 297(2): 149 - 150. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goldie, Y. Yazdanpanah, E. Losina, M. C. Weinstein, X. Anglaret, R. P. Walensky, H. E. Hsu, A. Kimmel, C. Holmes, J. E. Kaplan, et al. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire N. Engl. J. Med., September 14, 2006; 355(11): 1141 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Bini, J. Park, and F. Francois Use of Flexible Sigmoidoscopy to Screen for Colorectal Cancer in HIV-Infected Patients 50 Years of Age and Older. Arch Intern Med, August 14, 2006; 166(15): 1626 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. MacGowan, G. Eldridge, J. M. Sosman, R. Khan, T. Flanigan, B. Zack, A. Margolis, J. Askew, C. Fitzgerald, and Project START Study Group HIV Counseling and Testing of Young Men in Prison Journal of Correctional Health Care, July 1, 2006; 12(3): 203 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G Deeks Antiretroviral treatment of HIV infected adults. BMJ, June 24, 2006; 332(7556): 1489 - 1489. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Hsue and D. D. Waters What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection Circulation, December 20, 2005; 112(25): 3947 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hammer Clinical practice. Management of newly diagnosed HIV infection. N. Engl. J. Med., October 20, 2005; 353(16): 1702 - 1710. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chu, S. J. Gange, T. E. Yamashita, D. R. Hoover, J. S. Chmiel, J. B. Margolick, and L. P. Jacobson Individual Variation in CD4 Cell Count Trajectory among Human Immunodeficiency Virus-infected Men and Women on Long-term Highly Active Antiretroviral Therapy: An Application using a Bayesian Random Change-Point Model Am. J. Epidemiol., October 15, 2005; 162(8): 787 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Almond, P. G. Hoggard, D. Edirisinghe, S. H. Khoo, and D. J. Back Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals J. Antimicrob. Chemother., October 1, 2005; 56(4): 738 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lohrengel, F. Hermann, I. Hagmann, H. Oberwinkler, L. Scrivano, C. Hoffmann, D. von Laer, and M. T. Dittmar Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides J. Virol., August 15, 2005; 79(16): 10237 - 10246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chou, L. H. Huffman, R. Fu, A. K. Smits, and P. T. Korthuis Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 5, 2005; 143(1): 55 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Winston and M. Boffito The management of HIV-1 protease inhibitor pharmacokinetic interactions J. Antimicrob. Chemother., July 1, 2005; 56(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K Sullivan, H. Curtis, C. A Sabin, and M. A Johnson Newly diagnosed HIV infections: review in UK and Ireland BMJ, June 4, 2005; 330(7503): 1301 - 1302. [Full Text] [PDF]
|
|
|
|
|
|
D. Vlahov, N. Galai, M. Safaeian, S. Galea, G. D. Kirk, G. M. Lucas, and T. R. Sterling Effectiveness of Highly Active Antiretroviral Therapy among Injection Drug Users with Late-Stage Human Immunodeficiency Virus Infection Am. J. Epidemiol., June 1, 2005; 161(11): 999 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Manavi and P. D Welsby HIV testing BMJ, March 5, 2005; 330(7490): 492 - 493. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Elrefaei, M. D. McElroy, C. P. Preas, R. Hoh, S. Deeks, J. Martin, and H. Cao Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy J. Immunol., August 1, 2004; 173(3): 2184 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Yeni, S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. J. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, et al. Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel JAMA, July 14, 2004; 292(2): 251 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mocroft and J. D. Lundgren Starting highly active antiretroviral therapy: why, when and response to HAART J. Antimicrob. Chemother., July 1, 2004; 54(1): 10 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Rockstroh and S. Mauss Clinical perspective of fusion inhibitors for treatment of HIV J. Antimicrob. Chemother., May 1, 2004; 53(5): 700 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mocroft, A. N. Phillips, and J. D. Lundgren HIV Survival Benefit Associated with Earlier Antiviral Therapy Ann Intern Med, April 6, 2004; 140(7): 578 - 579. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Jacobson, R. J. Israel, I. Lowy, N. A. Ostrow, L. S. Vassilatos, M. Barish, D. N. H. Tran, B. M. Sullivan, T. J. Ketas, T. J. O'Neill, et al. Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542 Antimicrob. Agents Chemother., February 1, 2004; 48(2): 423 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Skolnik HIV Therapy -- What Do We Know, and When Do We Know It? N. Engl. J. Med., December 11, 2003; 349(24): 2351 - 2352. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. McGinnis, M. J. Fine, R. K. Sharma, M. Skanderson, J. H. Wagner, M. C. Rodriguez-Barradas, L. Rabeneck, and A. C. Justice Understanding Racial Disparities in HIV Using Data From the Veterans Aging Cohort 3-Site Study and VA Administrative Data Am J Public Health, October 1, 2003; 93(10): 1728 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Late Versus Early Testing of HIV--16 Sites, United States, 2000-2003 JAMA, July 23, 2003; 290(4): 455 - 457. [Full Text] [PDF]
|
|
|
|
 |
|
 When to Start Antiretrovirals: Another Look AIDS Clinical Care, June 1, 2003; 2003(601): 1 - 1. [Full Text]
|
|
|
|
|
|
H. C. Lane and J. D. Neaton When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data Ann Intern Med, April 15, 2003; 138(8): 680 - 681. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
